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Introduction
Mitogen-activated protein kinases (MAPKs) constitute a
conserved family of enzymes that regulate a large number
of physiological processes, including proliferation,
differentiation, development, immune function, stress
responses and apoptosis (Chang and Karin, 2001; Davis, 2000;
Johnson and Lapadat, 2002; Pearson et al., 2001; Wada and
Penninger, 2004). Mammalian MAPKs comprise three major
groups, which are classified on the basis of sequence similarity,
differential activation by agonists and substrate specificity.
These are the p42/p44 MAPKs or extracellular signal-regulated
kinases (ERKs), the Jun N-terminal kinases (JNK1, JNK2,
JNK3) and the p38 MAPKs (a, b, d and g) (Cohen, 1997).
MAPKs are activated by phosphorylation on threonine and
tyrosine residues within a conserved signature sequence TxY
by a MAPK kinase (MKK or MEK), which is in turn
phosphorylated and activated by a MAPK kinase kinase
(MKKK or MEKK) (Marshall, 1994; Qi and Elion, 2005). The
component kinases of the MAPK module may interact
sequentially, but can also be organised into signalling
complexes via interactions with specific scaffold proteins
(Garrington and Johnson, 1999; Morrison and Davis, 2003).
One conserved property of MAPK signalling is that the
magnitude and duration of MAPK activation is a crucial
determinant of biological outcome (Ebisuya et al., 2005;
Marshall, 1995; Sabbagh, Jr et al., 2001). This highlights the
importance of negative regulatory mechanisms in determining
the output of MAPK pathways, and it is now clear that a major
point of control occurs at the level of the MAPK itself, via the
intervention of protein phosphatases. Because modification of
both the threonine residue and the tyrosine residue within
the activation motif is required for MAPK activity,
dephosphorylation of either residue inactivates these enzymes.
This can be achieved by tyrosine-specific phosphatases,
serine-threonine phosphatases or dual-specificity (Thr/Tyr)
phosphatases, and work using a variety of model organisms has
demonstrated that all three classes of protein phosphatase can
regulate MAPKs in vivo (Keyse, 2000; Saxena and Mustelin,
2000). However, the largest group of phosphatases dedicated
to the regulation of MAPK signalling in vertebrates are the
dual-specificity MAPK phosphatases (MKPs).
The MKP subfamily of dual-specificity phosphatases
The MKPs constitute a structurally distinct subgroup of 11
proteins within the larger family of dual-specificity protein
phosphatases (DUSP or VHR-like cysteine-dependent protein
phosphatases) encoded in the human genome (Alonso et al.,
2004). The subgroup comprises ten active enzymes and one
protein, DUSP24/MK-STYX, that has many features of an
MKP but lacks the active site cysteine that is essential for
catalysis (Wishart and Dixon, 1998). All MKPs share a
common structure (see Fig. 1A), comprising a C-terminal
catalytic domain that shows sequence similarity to the
prototypic dual-specificity protein phosphatase VH-1 of
vaccinia virus and an N-terminal domain containing two
regions of sequence similarity to the catalytic domain of the
Cdc25 phosphatase (Keyse and Ginsburg, 1993). The latter
similarity reflects a common evolutionary origin for this
domain of the MKPs and Cdc25 in the rhodanese family of
sulphotransferases (Bordo and Bork, 2002). The N-terminal
MKP domain also contains a cluster of basic amino-acid
residues, which play an important role in MAPK substrate
A structurally distinct subfamily of ten dual-specificity
(Thr/Tyr) protein phosphatases is responsible for the
regulated dephosphorylation and inactivation of mitogen-
activated protein kinase (MAPK) family members in
mammals. These MAPK phosphatases (MKPs) interact
specifically with their substrates through a modular kinase-
interaction motif (KIM) located within the N-terminal non-
catalytic domain of the protein. In addition, MAPK binding
is often accompanied by enzymatic activation of the C-
terminal catalytic domain, thus ensuring specificity of
action. Despite our knowledge of the biochemical and
structural basis for the catalytic mechanism of the MKPs,
we know much less about their regulation and physiological
functions in mammalian cells and tissues. However, recent
studies employing a range of model systems have begun to
reveal essential non-redundant roles for the MKPs in
determining the outcome of MAPK signalling in a variety
of physiological contexts. These include development,
immune system function, metabolic homeostasis and the
regulation of cellular stress responses. Interestingly, these
functions may reflect both restricted subcellular MKP
activity and changes in the levels of signalling through
multiple MAPK pathways. 
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recognition and binding (Tanoue et al., 2000; Tanoue et al.,
2002). 
On the basis of sequence similarity, gene structure, substrate
specificity and subcellular localisation, the MKPs can be
further subdivided into three groups (Fig. 1B). The first
comprises four inducible nuclear MKPs encoded by DUSP1
(MKP-1), DUSP2 (PAC-1), DUSP4 (MKP-2) and DUSP5
(hVH3). The second group contains three closely related
cytoplasmic ERK-specific MKPs encoded by DUSP6 (MKP-
3), DUSP7 (MKP-X) and DUSP9 (MKP-4). The third group
Journal of Cell Science 119 (22)
contains three MKPs encoded by DUSP8 (hVH5), DUSP10
(MKP-5) and DUSP16 (MKP-7); these selectively inactivate
the stress-activated MAPK isoforms (Camps et al., 2000;
Keyse, 2000; Theodosiou and Ashworth, 2002).
While our knowledge of the biochemical and structural basis
of MKP catalysis and substrate specificity has greatly increased
over the past few years, progress in our understanding of the
physiological roles of these enzymes in mammalian cells and
tissues has been somewhat slow. This is due to the large
number of MKPs with overlapping substrate specificities,
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Fig. 1. Classification, domain structure and phylogenetic analysis of the dual-specificity MAPK phosphatases. (A) Domain structures of the ten
catalytically active DUSP proteins and MK-STYX. In addition to the N-terminal non-catalytic domain containing the Cdc25/rhodanese-
homology region and the catalytic site, the positions of the conserved kinase-interaction motif (KIM), nuclear localisation signals (NLS),
nuclear export signals (NES) and PEST sequences are indicated. The three subgroups revealed by the phylogenetic analysis are indicated by the
background colour. (B) DUSP sequence analysis. Human DUSP amino acid sequences were aligned using CLUSTALW
(http://align.genome.jp/) and a phylogenetic tree was generated. The three subgroups of DUSP proteins together with defining properties are
indicated by the coloured ovals.
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combined with a lack of relevant mammalian models. Here, we
focus on recent progress using a variety of approaches,
including the generation of mouse gene knockouts, which has
begun to yield insights into the regulation and functions of the
MKPs and will provide experimental platforms to enable
us to determine whether these enzymes play a part in the
development of human diseases including immune disorders,
diabetes and cancer.
MKPs in immune function, stress responses and
metabolic homeostasis
DUSP10/MKP-5 and JNK in innate and adaptive
immunity
The first MKP to be identified as specific for the stress-
activated MAPKs JNK and p38 in mammalian cells was
DUSP8 (also known as hVH5 or M3/6) (Muda et al., 1996).
This subgroup of MKPs was expanded by the subsequent
characterisation of the related phosphatases DUSP10/MKP-5
and DUSP16/MKP-7 (Masuda et al., 2001; Tanoue et al., 1999;
Tanoue et al., 2001; Theodosiou et al., 1999).
Only DUSP10/MKP-5 has been studied genetically in
mammals. DUSP10/MKP-5 was originally identified as a
phosphatase capable of regulating JNK and p38 MAPKs, but
not ERK1 or ERK2, both in vitro and in vivo (Tanoue et al.,
1999; Theodosiou et al., 1999). Interestingly, DUSP10/MKP-
5 mRNA is induced in a mouse macrophage cell line by
bacterial lipopolysaccharide (LPS). In T cells, it is
constitutively expressed in naive CD4 T cells but
downregulated 24 hours after T-cell activation (Zhang et al.,
2004). Deletion of the murine gene encoding DUSP10/MKP-
5 does not cause developmental defects, nor is this enzyme
essential for the development of the immune system. However,
both the Th1 and Th2 subsets of T-helper cells lacking
DUSP10/MKP-5 have significantly higher levels of JNK
activity, whereas p38 MAPK activity is unaffected. Increased
JNK activity is also seen in DUSP10/MKP-5–/– macrophages
after LPS treatment, which induces innate responses via Toll-
like receptor (TLR) 4. This indicates that the inactivation
of JNK by DUSP10/MKP-5 regulates innate or adaptive
immune responses. Indeed, peritoneal macrophages from
DUSP10/MKP-5–/– animals, when challenged with LPS,
produce increased levels of the pro-inflammatory cytokines
interleukin-6 (IL-6) and tumor necrosis factor (TNF), and
TLR2 and TLR3 signalling also results in increased levels of
these cytokines. Moreover, injection of LPS into
DUSP10/MKP-5–/– mice leads to increased serum TNF
production (Zhang et al., 2004).
Another function of the innate immune system is the
activation of antigen-specific T cells. In this regard, the T-
cell-priming activity of LPS-treated antigen-presenting cells
(APCs) lacking DUSP10/MKP-5 is greatly enhanced.
DUSP10/MKP-5 is therefore a negative regulator of innate
immunity (Zhang et al., 2004). In the adaptive immune
response, CD4 T cells from DUSP10/MKP-5–/– mice show
reduced proliferative responses to activating stimuli, which
indicates that DUSP10/MKP-5 is required for proper T cell
expansion. To examine the role of DUSP10/MKP-5 in effector
T-helper-cell function, wild-type or knockout CD4 T cells were
differentiated into Th1 and Th2 cells. These T-helper-cell
subtypes are defined on the basis of the specific cytokines they
produce. Th1 cells produce interferon g (IFNg) and IL12
whereas Th2 cells produce IL3, IL4 and IL13. When compared
with wild-type cells, DUSP10/MKP-5–/– Th1 and Th2 cells
were found to produce increased levels of IFNg and IL-4,
respectively. DUSP10/MKP-5–/– CD8 T cells (also known as
cytotoxic or killer T cells) also produce more IFNg and TNF
in vitro. These results indicate that cytokine expression in
effector T cells is negatively regulated by DUSP10/MKP-5.
Finally, the effects of loss of DUSP10/MKP-5 in several in
vivo immune and autoimmune models have been characterised.
Immunisation with myelin oligodendrocyte glycoprotein
(MOG) peptide induces experimental autoimmune
encephalomyelitis (EAE). Compared with wild-type mice,
DUSP10/MKP-5–/– animals exhibit a markedly reduced
incidence and severity of disease, which suggests that this
phosphatase plays a crucial role in the generation and/or
expansion of autoreactive T cells in EAE (Zhang et al., 2004).
This finding, together with the reduced proliferative capacity
of naive T-helper cells in these animals, indicates a positive
regulatory role for DUSP10/MKP-5 in these cells.
DUSP10/MKP-5 may therefore have distinct roles depending
on the immune cell population studied. Note also that one
cannot assign JNK as the preferred target for DUSP10/MKP-
5 activity unless the levels of activation for each MAPK
pathway are measured in all cell types.
To examine the role of DUSP10/MKP-5 during T-cell-
mediated immunity to infection, Zhang et al. also infected
animals with lymphocytic choriomeningitis virus (LCMV).
Although DUSP10/MKP-5–/– mice clear virus and exhibit little
difference in the primary T-cell response, they respond to
secondary LCMV challenge by producing significantly
elevated levels of serum TNF. This is probably responsible for
the immune-mediated death of these animals 2-4 days after
challenge.
DUSP10/MKP-5 thus negatively regulates the JNK
signalling pathway and serves important roles as a negative
regulator of innate immune responses and a regulator of proper
T cell function. It is not yet clear whether, as suggested by
biochemical studies, DUSP10/MKP-5 is also involved in the
regulation of p38 MAPK activity or plays any additional role
in the regulation of mammalian stress responses. No doubt
these aspects of DUSP10/MKP-5 function will be the subject
of future studies as will the generation and study of mice
lacking the genes encoding the other MKPs that selectively
inactivate the stress-activated MAPKs.
Inducible nuclear MKPs as regulators of immune
function
The inducible nuclear MKPs constitute a subfamily of four
enzymes: DUSP1/MKP-1, DUSP2/PAC-1, DUSP4/MKP-2
and DUSP5. An early disappointment in the genetic dissection
of MKP function came with a report that mice lacking the
prototypic inducible nuclear phosphatase DUSP1/MKP-1
appear normal and fertile (Dorfman et al., 1996). Furthermore,
cells derived from these animals show no evidence of abnormal
regulation of the ERK pathway. However, although
DUSP1/MKP-1 was originally shown to dephosphorylate the
ERK1/2 MAPKs in vitro, it can also target the JNKs and p38
MAPKs (Franklin and Kraft, 1997; Groom et al., 1996; Slack
et al., 2001). Despite this, neither the activities of JNK or p38
nor stress-induced endpoints were originally studied in
DUSP1/MKP-1-null animals. However, several groups have
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recently addressed this question and provided compelling
evidence that DUSP1/MKP-1 plays a key role in regulation of
the physiological output of signalling through the ERK, JNK
and p38 MAPK pathways.
First, both mouse embryo fibroblasts (MEFs) and primary
alveolar macrophages from mice lacking DUSP1/MKP-1 show
increased JNK and p38 activities in response to a range of
activating stimuli compared with wild-type cells (Wu and
Bennett, 2005; Zhao et al., 2005). Furthermore, MEFs lacking
DUSP1/MKP-1 display lower growth rates owing to increased
cell death and are also more sensitive to anisomycin- or
hydrogen-peroxide-induced apoptosis (Wu and Bennett,
2005; Zhou et al., 2006). These results demonstrate that
DUSP1/MKP-1 promotes cell survival by attenuating
signalling through the stress-activated MAPK pathways.
The finding that loss of DUSP1/MKP-1 greatly increases the
duration of p38 activation in LPS-treated macrophages
suggested that this phosphatase might regulate inflammation
during the innate immune response (Zhao et al., 2005). Recent
work now confirms such a role, because mice lacking
DUSP1/MKP-1 respond to LPS by overproducing a subset of
cytokines, including TNF, IL6 and IL10, and are acutely
sensitive to lethal endotoxic shock. They also exhibit a marked
increase in both the incidence and severity of experimentally
induced autoimmune arthritis (Chi et al., 2006; Hammer et al.,
2006; Salojin et al., 2006; Zhao et al., 2006). Thus
DUSP1/MKP-1 controls the levels of both pro-inflammatory
(TNF) and anti-inflammatory (IL10) cytokines in response to
LPS (Fig. 2A). The overproduction of TNF in DUSP1/MKP-
1–/– macrophages is seen only at early time points after
exposure to LPS. By contrast, elevated levels of IL10 are seen
at all time points following LPS challenge. The reduction in
TNF levels seen at these later time points most probably
reflects the known function of IL10 in suppressing production
of TNF, macrophages responding to the IL10 in an autocrine
and/or paracrine fashion. In support of this mechanism,
exposure of DUSP1/MKP-1–/– macrophages to a neutralising
antibody directed against IL10 prior to LPS challenge enhances
TNF mRNA levels (Chi et al., 2006). This indicates a dynamic
balance between MAPK activation and the activity of
DUSP1/MKP-1 in the temporal regulation of pro- and anti-
inflammatory mediators.
Finally, it has been known for some time that synthetic
glucocorticoids such as dexamethasone are potent inducers of
DUSP1/MKP-1 expression (Kassel et al., 2001; Lasa et al.,
2002). Because these agents inhibit the expression of pro-
inflammatory genes and are widely used in the treatment of
inflammatory disease, it was suggested that at least part of the
therapeutic action of these drugs might be mediated by
induction of DUSP1/MKP-1 (Clark, 2003). A recent study
has now shown that the suppression of a subset of pro-
inflammatory genes including those encoding TNF,
cyclooxygenase-2, IL-1a and IL-1b in response to
dexamethasone is reduced in macrophages from DUSP1/MKP-
Journal of Cell Science 119 (22)
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Fig. 2. Physiological roles of DUSP1/MKP-1 in immunity and metabolic regulation. (A) In macrophages, LPS signals through Toll-like
receptor (TLR), which engages the adaptor proteins MyD88 and TRIF. This leads to an early response, in which p38 MAPK and JNK are
activated and contribute to the expression of TNF, and is followed by induction of MKP-1 expression, which serves to downregulate p38/JNK
activities and TNF production. At later times, as MKP-1 expression declines, the levels of p38 MAPK and JNK activity remain higher than in
unstimulated cells and promote IL10 expression. (B) In insulin-responsive tissues, MKP-1 regulates multiple MAPK pathways in the nucleus,
and thus controls the expression of genes involved in fatty acid metabolism and energy expenditure. The activities of MAPKs in the cytosol are
not subject to regulation by MKP-1. Therefore, negative feedback controls, such as the phosphorylation of IRS by JNK, are unaffected. 
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1-knockout mice and that the in vivo anti-inflammatory effects
of dexamethasone on zymosan-induced inflammation are also
impaired in these animals. These results demonstrate that the
expression of DUSP1/MKP-1 is necessary for the inhibition of
pro-inflammatory signalling and that this is at least partly
responsible for the anti-inflammatory effects of dexamethasone
in vivo (Abraham et al., 2006). 
It is interesting to compare the immune defects seen in the
DUSP1/MKP-1–/– animals with those in the DUSP10/MKP-
5 knockout (Zhang et al., 2004). Both phosphatases have
essential, non-redundant functions in regulating immune
function despite being able to dephosphorylate and inactivate
the same subset of MAPKs. However, there may be
significant differences in the way that these two enzymes
differentially regulate MAPK pathways. Loss of
DUSP10/MKP-5 has a greater effect on signalling through
the JNK pathway, whereas the effects of knocking out
DUSP1/MKP-1 in immune cells are more consistent with
increased signalling through the p38 MAPK pathway. For
instance, both the overproduction of cytokines and expression
of co-stimulatory molecules in LPS-stimulated
DUSP1/MKP-1–/– macrophages are abrogated by SB203580,
a specific inhibitor of p38 MAPK, which indicates that this
pathway is a major target of DUSP1/MKP-1 in these cells
(Chi et al., 2006; Hammer et al., 2006). Note, however, that
one group has observed attenuation of IL12 levels in
DUSP1/MKP-1–/– macrophages stimulated with LPS (Zhao et
al., 2006). This is surprising, because the production of this
cytokine has been closely linked to levels of p38 MAPK
activity (Lu et al., 1999). Finally, it should be remembered
that a major difference between DUSP10/MKP-5 and
DUSP1/MKP-1 is the ability of the latter to influence the
activity of all three classes of MAPK and the combinatorial
regulation of these pathways by DUSP1/MKP-1 relative to
DUSP10/MKP-5 may account for the distinct effects of gene
deletion on endpoints such as cytokine production.
Of the inducible MKPs, the enzyme most closely
associated with cells of the immune system is DUSP2/PAC-
1. This phosphatase was originally identified as a mitogen-
inducible gene in human T cells that encodes a dual-
specificity phosphatase with activity towards ERK1/2 and
p38 MAPKs in vitro and in vivo (Chu et al., 1996; Rohan et
al., 1993; Ward et al., 1994). More recently, DUSP2/PAC-1
was found to be a transcriptional target of the p53 pathway
in response to either growth-factor withdrawal or oxidative
stress. The resulting inactivation of ERK2 MAPK has been
implicated in p53-mediated apoptosis (Yin et al., 2003).
Animals lacking DUSP2/PAC-1 have a complex phenotype
with respect to the regulation of MAPK activities in immune
effector cells and this has revealed an unexpected positive
regulatory function for this enzyme in the induction and
maintenance of certain inflammatory responses (Jeffrey et al.,
2006).
Micro-array analysis of gene expression in wild-type versus
DUSP2/PAC-1-null macrophages following LPS stimulation
revealed a significant deficit in the expression of pro-
inflammatory mediators and cytokines including IL-6, IL12a,
cyclooxygenase-2, IL-1b and inflammatory chemokines in
the null cells. Furthermore, this deficit can be rescued by
re-expression of wild-type but not a catalytically inactive
mutant of DUSP2/PAC-1 (Jeffrey et al., 2006). To test the
physiological role of DUSP2/PAC-1, Jeffrey et al. assessed
basic features of the immune system such as lymphoid tissue
development and lymphocyte/granulocyte numbers in blood
and bone marrow and found them to be normal. They then
assessed the null mice in an autoimmune (K/BxN serum-
induced) model of inflammatory arthritis in which pathology
is driven by effector leukocytes such as mast cells, neutrophils
and macrophages. Whereas wild-type mice injected with
arthritogenic K/BxN serum develop inflammatory arthritis
within 2 days and show inflammatory cell infiltration and
eventual joint destruction, DUSP2/PAC-1-null littermates are
protected and show greatly diminished pathological features of
arthritis.
Despite biochemical evidence linking DUSP2/PAC-1 to
negative regulation of ERK and p38 MAPKs in vitro, both mast
cells and macrophages derived from animals lacking PAC-1
display reduced levels of activated ERK and p38. By contrast,
levels of activated JNK, which had not previously been
identified as a DUSP2/PAC-1 substrate, are considerably
higher in LPS-stimulated macrophages (Jeffrey et al., 2006).
Pharmacological inhibition of JNK activity in these cells leads
to a significant increase in ERK activity, which suggests that,
by elevating JNK activity, DUSP2/PAC-1 loss may indirectly
decrease the activity of ERK through an undefined mechanism.
With respect to the latter, it is now clear that direct crosstalk
between MAPK pathways can occur in cells during both stress-
and growth-factor-induced signalling (Shen et al., 2003; Zhang
et al., 2001). Despite this apparent selectivity of DUSP2/PAC-
1 for inactivation of JNK, co-immunoprecipitation experiments
using an inactive mutant of DUSP2/PAC-1 detected
interactions with ERK, p38 and JNK1 in EGF-stimulated cells.
However, a recent study has indicated that, although
DUSP2/PAC-1 interacts efficiently with p38, it fails to
dephosphorylate and inactivate this MAPK in vitro (Zhang et
al., 2005).
The recently generated knockouts thus have provided
contrasting and apparently contradictory immune system
phenotypes. Loss of DUSP10/MKP-5 causes elevation of JNK
activity and enhanced cytokine production, whereas loss of
DUSP1/MKP-1 elevates both p38 and JNK activities, resulting
in defects in innate immune cell responses. By contrast, the
combination of increased JNK activation, combined with a
reduction of ERK and p38 activities seen in DUSP2/PAC-1-
null animals, translates into a quite different outcome: a deficit
in cytokine gene expression accompanied by protection from
inflammatory arthritis. It will be important to explore the
apparent discordance between the effects of loss of genes
encoding MKPs on MAPK signalling and the biochemical
studies of DUSP10/MKP-5 and DUSP2/PAC-1 substrate
specificity. These studies give a strong indication that MKP
function is complex and that the ability of these enzymes to
differentially modulate multiple MAPK pathways can give rise
to quite distinct biological outcomes.
MKP-1 and metabolic homeostasis
Given that DUSP1/MKP-1 is widely expressed during
development and in adult tissues (Carrasco and Bravo, 1993;
Kwak et al., 1994), it would be surprising if its functions were
restricted to cells of the immune system. Recent work, again
using the DUSP1/MKP-1–/– mice, indicates that this
phosphatase also plays a key role in regulating MAPK
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signalling in insulin-responsive tissues. The effects of
DUSP1/MKP-1 deletion on MAPK signalling in adult tissues
are complex. Hyperactivation of JNK and p38 is seen in white
adipose tissue (WAT), skeletal muscle and liver whereas ERK
activity is elevated only in WAT and muscle (Wu et al., 2006).
Furthermore, DUSP1/MKP-1-null animals gain weight
following weaning onto a chow diet at a significantly lower rate
than wild-type animals and are also resistant to obesity induced
by a high-fat diet. Surprisingly, despite enhanced MAPK
activities in insulin-responsive tissues, DUSP1/MKP-1–/– mice
remain susceptible to the development of glucose intolerance
and hyperinsulinemia caused by high-fat feeding. Thus,
DUSP1/MKP-1 must regulate body mass independently of the
regulation of glucose homeostasis.
At first sight these results seem difficult to reconcile with
recent work on the role of JNK signalling in animal models,
because elevated JNK activity has been associated with obesity
and insulin resistance, and mice lacking JNK1 are both
resistant to diet-induced obesity and also exhibit insulin
sensitivity (Hirosumi et al., 2002). However, two features of
the regulation of MAPK activities by DUSP1/MKP-1 could
account for the uncoupling of diet-induced obesity from
glucose intolerance (Fig. 2B).
First, all three of the MAPKs targeted by DUSP1/MKP-1
are capable of affecting metabolic regulation. p38 MAPK can
regulate energy expenditure via activation of peroxisome
proliferator-activated receptor gamma (PPARg) coactivator 1a
(PGC-1a) (Fan et al., 2004) and mice lacking ERK1 display
resistance to diet-induced obesity coupled with protection from
the development of insulin resistance (Bost et al., 2005). Thus,
the phenotype of the DUSP1/MKP-1–/– mice probably reflects
complex changes in the activities of all three major classes of
MAPK in target tissues rather than hyperactivation of one
MAPK pathway in isolation (Wu et al., 2006).
Second, DUSP1/MKP-1 is a nuclear phosphatase and it may
not inactivate the cytosolic pools of activated MAPK, which
participate in the control of insulin-responsive glucose uptake.
Indeed Wu et al. did not see any changes in the phosphorylation
of insulin receptor substrate 1 (IRS-1), which is targeted by
JNK, in DUSP1/MKP-1–/– mice. They also observed the
nuclear accumulation of phosphorylated JNK in livers from
these animals and this correlated with enhanced nuclear
Jun phosphorylation and activation in DUSP1/MKP-1–/–
hepatocytes (Wu et al., 2006). Thus, the increased activity of
all three classes of MAPK in the nucleus might increase the
transcription of genes that regulate fatty acid metabolism and
energy expenditure.
There are alternative explanations, which require further
investigation. First, a role for the activity of DUSP1/MKP-1 in
tissues other than those studied cannot be excluded. In
particular, DUSP1/MKP-1 is expressed in regions of the brain
including the pineal gland and hypothalamus, where changes
in MAPK signalling might lead to altered behavior and thus
affect energy expenditure (Price et al., 2004). Second, the
mixed genetic background may play a role in the expression of
both the metabolic and immune phenotypes seen in the
DUSP1/MKP-1 knockout. It will certainly be interesting to
study the effects of DUSP1/MKP-1 deletion in an inbred strain
and also to employ tissue-specific deletion of this gene to
dissect the target tissue(s) and signalling pathways responsible
for this clinically interesting phenotype.
The cytoplasmic ERK-specific MKPs play important
roles during early development
DUSP9/MKP-4 is essential for placental development
and function
The subfamily of cytoplasmic ERK-specific MKPs comprises
three closely related proteins encoded by DUSP6 (MKP-3),
DUSP7 (MKP-X) and DUSP9 (MKP-4). DUSP6/MKP-3
specifically inactivates ERK1 and ERK2, whereas biochemical
studies indicate that both DUSP7/MKP-X and DUSP9/MKP-
4 may also be able to inactivate p38 MAPK (Camps et al.,
1998; Dickinson et al., 2002b; Dowd et al., 1998; Groom et al.,
1996). Deletion of the murine DUSP9/MKP-4 gene causes
embryonic lethality at mid-gestation (Christie et al., 2005).
This is a consequence of placental insufficiency caused by
a failure of labyrinth development. The appearance of this
defect correlates exactly with the timing of expression of
DUSP9/MKP-4 in the normal placenta, in which it is first
detected in the ectoplacental cone and chorion, and later
appears in the trophoblast giant cells, spongiotrophoblast and
labyrinth as these lineages differentiate (Christie et al., 2005;
Dickinson et al., 2002b).
Despite this clear developmental defect, no evidence could
be found for abnormal phosphorylation or activation of either
ERK or p38 MAPKs in the placenta. This indicates that either
the timing of any abnormal signalling events is restricted or
that the magnitude of the changes in the affected cells and
tissues is too small to detect. Interestingly, disruption of either
MEK1 (Giroux et al., 1999), an upstream activator of ERK1/2,
or p38a MAPK (Adams et al., 2000) gives rise to placental
phenotypes that are strikingly similar to that seen following
loss of DUSP9/MKP-4. This indicates that abnormal regulation
of either or both of these signalling cascades is involved.
Further studies involving an examination of well-characterised
patterns of marker gene expression during placental
development may shed some light on the underlying defect in
tissues lacking DUSP9/MKP-4.
Tetraploid aggregation has been used to bypass the placental
defect caused by loss of this phosphatase. Despite the normally
high levels of DUSP9/MKP-4 expression in the developing
liver and in the kidneys and testes of adult mice, the
DUSP/MKP-4-null animals generated in this way develop to
term, have no obvious phenotype and are fertile (Christie et al.,
2005). Furthermore, DUSP9/MKP-4-expressing tissues such
as the embryonic liver, kidney and testis, show no abnormal
morphology in the null animals. Thus, essential non-redundant
functions for DUSP9/MKP-4 appear to be restricted to the
extra-embryonic tissues during development. However, it is
possible that DUSP9/MKP-4 is required to regulate MAPK
signalling in adult tissues, perhaps during as-yet-undefined
conditions of stress.
DUSP6/MKP-3 is a negative feedback regulator of
fibroblast growth factor signalling
The first clues about the regulation and physiological function
of DUSP6/MKP-3 came from studies of the pattern of its
expression in developing mouse embryos (Dickinson et al.,
2002a). Dynamic patterns of DUSP6/MKP-3 mRNA
expression are detected in limb bud and branchial arch
mesenchyme, midbrain/hindbrain isthmus, and nasal, dental,
hair and mammary placodes. Most of these are known sites of
fibroblast growth factor (FGF) signalling, which indicates that
Journal of Cell Science 119 (22)
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both the expression and function of DUSP6/MKP-3 could be
related to this key pathway during early development.
Subsequent studies have reinforced the link between FGF
signalling and DUSP6/MKP-3 function.
In chicken embryos, tissue ablation and transplantation
have revealed that the apical ectodermal ridge (AER) and
Henson’s node, both of which produce FGFs, are essential for
DUSP6/MKP-3 expression in the developing limb and
nervous system, respectively (Eblaghie et al., 2003;
Kawakami et al., 2003). Furthermore, expression of
DUSP6/MKP-3 is also regulated by FGF in the murine
isthmic organiser during neural tube development and in the
developing chick somite (Echevarria et al., 2005; Smith et
al., 2005). MKP-3 could therefore be a crucial negative
feedback regulator of FGF signalling. However, it is less clear
which intracellular signalling pathway(s) downstream of the
FGF receptor promote the expression of DUSP6/MKP-3.
Essential roles have been proposed for both ERK-MAPK
(Eblaghie et al., 2003; Gomez et al., 2005; Smith et al., 2005;
Tsang et al., 2004) and PI3-kinase (Echevarria et al., 2005;
Kawakami et al., 2003) signalling. These studies have
involved a range of tissues from different model systems,
often using different pharmacological inhibitors of the
ERK and PI3-kinase pathways, and this may explain the
apparently contradictory data (Smith et al., 2006). In
addition, evidence for the involvement of retinoic acid and
maternal b-catenin has been obtained (Moreno and Kintner,
2004; Tsang et al., 2004). Detailed studies of the interface
between intracellular signalling pathways and the
DUSP6/MKP-3 promoter will be required to clarify these
issues. 
Overexpression of DUSP6/MKP-3 in the chick limb and
neural plate causes developmental abnormalities, whereas
knocking it down by using RNAi results in increased
levels of apoptosis in limb-bud mesenchyme (Eblaghie et
al., 2003; Kawakami et al., 2003). DUSP6/MKP-3 might
therefore regulate the developmental outcome of FGF
signalling by setting an appropriate level of activated
ERK MAPK. In support of this notion, both gain- and
loss-of function studies in zebrafish embryos reveal an
essential role for DUSP6/MKP-3 in limiting the extent of
ERK-MAPK signalling in response to FGF, interference
with this negative regulation causing disruption of
dorsoventral patterning at the onset of gastrulation (Tsang et
al., 2004).
Concluding remarks and perspectives
It is now clear that, rather than comprising a group of related
enzymes with overlapping and redundant functions, the MKPs
have distinct and essential roles, which impinge on a wide
range of physiological outputs of MAPK signalling. These
include immune function, stress responses and metabolic
regulation (Table 1). Interestingly, the phenotypes observed in
animals lacking a single MKP may reflect complex changes in
the activities of multiple MAPK pathways, suggesting MAPK
signalling is integrated at the level of regulation by MKPs. In
addition, the differential subcellular localisation of MKPs may
facilitate spatio-temporal regulation of MAPK activities. The
demonstration that deletion of MKP-1 selectively affects
nuclear JNK activity to regulate energy expenditure
demonstrates the importance of spatially restricted MKP
activity in determining the physiological outcome of
signalling. 
Clearly, these studies are only a beginning in terms of
providing us with a full understanding of MKP function. There
is no doubt that, as the animal models are more widely studied
and additional knockouts are produced, the repertoire of known
MKP functions will expand. In the immediate future there are
several issues to be resolved. These include the reasons for the
apparent discordance between the biochemical activities of
MKPs such as DUSP2/PAC-1 and the observed changes in
MAPK activities in animals lacking this gene, and why
elevation of JNK signalling on deletion of this phosphatase
produces quite different effects on immune function compared
with loss of other JNK-specific MKPs, such as DUSP10/MKP-
5. In addition to different combinatorial effects on MAPK
signalling, one explanation for the latter may be that, although
distinct MKPs share common MAPK substrates, their activities
may be directed through selective recruitment to scaffolding
proteins. Finally, the effects of loss of MKP function on the
immune system and metabolic regulation raise the possibility
that selective pharmacological inhibition of these enzymes has
therapeutic potential and should greatly stimulate interest in
this class of dual-specificity protein phosphatases as candidates
for drug targets.
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Table 1. Nomenclature, key properties and mouse knockout phenotypes for the dual-specificity MAP kinase phosphatases
Gene MKP Trivial names Localisation Substrate MAPKs Knockout phenotype
DUSP1 MKP-1 CL100, 3CH134, erp, hVH1 Nuclear ERK1/2, p38, JNK Immune defects and
resistance to obesity
DUSP4 MKP-2 hVH2, TYP1, STY8 Nuclear ERK1/2, p38, JNK N/D
DUSP2 N/A PAC1 Nuclear ERK1/2, p38 Resistant to immune
inflammation
DUSP5 N/A hVH3, B23 Nuclear ERK1/2 N/D
DUSP6 MKP-3 PYST1, rVH6 Cytoplasmic ERK1/2 N/D
DUSP7 MKP-X PYST2, B59 Cytoplasmic ERK1/2 N/D
DUSP9 MKP-4 PYST3 Cytoplasmic ERK1/2 > p38 Midgestation lethality – 
placental insufficiency
DUSP8 N/A hVH5, HB5, M3/6 Nuclear/cytoplasmic JNK, p38 N/D
DUSP10 MKP-5 N/A Nuclear/cytoplasmic JNK, p38 Defects in innate and
adaptive immunity
DUSP16 MKP-7 N/A Nuclear/cytoplasmic JNK, p38 N/D
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